BiotechTube
BrYet

BrYet

Cambridge, United States· Est.
bryetpharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

BrYet is an early-stage biotechnology company pioneering a physics-based approach to curing metastatic cancer. Its core strategy leverages two proprietary platforms—Transport Oncophysics and Nanoporous Silicon MicroParticles (NSMP)—to design therapeutics that overcome biological barriers and drug resistance. The company's lead candidate, ML-016, has shown unprecedented curative efficacy in preclinical models of lung and liver metastases and has recently entered Phase 1/2 clinical trials following an IND filing.

Oncology

Technology Platform

Two proprietary platforms: 1) Transport Oncophysics, a mathematical framework to model drug transport and identify cancer-specific transport phenotypes; and 2) Nanoporous Silicon MicroParticles (NSMP), bio-erodible, engineered particles for targeted drug delivery to tumors, particularly lung and liver metastases.

Opportunities

The primary opportunity is addressing the vast, unmet need for curative therapies in metastatic cancer, a market worth hundreds of billions.
Success with ML-016 would validate BrYet's novel transport-focused platform, enabling rapid expansion into other metastatic indications and creating significant partnership or acquisition value.

Risk Factors

The major risks are clinical failure of ML-016, as preclinical efficacy may not translate to humans, and platform risk associated with the unproven transport oncophysics paradigm.
Financial risk is also high as a pre-revenue company dependent on investor funding.

Competitive Landscape

BrYet competes in the crowded oncology space but with a differentiated, physics-based approach targeting drug delivery and transport phenotypes. It faces competition from all major oncology drug developers, particularly those in nanomedicine and targeted therapies, but its claimed curative preclinical efficacy in metastases is a unique differentiator if clinically validated.

More companies in Drug Delivery & Formulation →More companies in United States →